<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-BX3V6XLQ/d3885879-bc0e-4ecd-92ab-3a0f11000bbc/PDF"><dcterms:extent>209 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-BX3V6XLQ/d2422436-4789-40d6-b4a4-96b4af30b53c/TEXT"><dcterms:extent>46 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1994-2025"><edm:begin xml:lang="en">1994</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-BX3V6XLQ"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-46R7GGHL" /><dcterms:issued>2000</dcterms:issued><dc:creator>Vrhovec, Levin</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:39</dc:format><dc:format xml:lang="sl">str. 33-50</dc:format><dc:identifier>ISSN:0025-8121</dc:identifier><dc:identifier>COBISSID:11474137</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-BX3V6XLQ</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Medicinski razgledi</dc:publisher><dcterms:isPartOf xml:lang="sl">Medicinski razgledi</dcterms:isPartOf><dc:subject xml:lang="en">Adverse effects</dc:subject><dc:subject xml:lang="en">Antineoplastic agents</dc:subject><dc:subject xml:lang="en">Blood</dc:subject><dc:subject xml:lang="en">Chemically induced</dc:subject><dc:subject xml:lang="sl">cistatin</dc:subject><dc:subject xml:lang="en">Creatinine</dc:subject><dc:subject xml:lang="en">Cystatins</dc:subject><dc:subject xml:lang="en">diagnostika</dc:subject><dc:subject xml:lang="en">Glomerular filtration rate</dc:subject><dc:subject xml:lang="sl">kemoterapija</dc:subject><dc:subject xml:lang="en">Kidney diseases</dc:subject><dc:subject xml:lang="en">Kidney function tests</dc:subject><dc:subject xml:lang="sl">ledvice</dc:subject><dc:subject xml:lang="en">Metabolic clearance rate</dc:subject><dc:subject rdf:resource="http://www.wikidata.org/entity/Q974135" /><dcterms:temporal rdf:resource="1994-2025" /><dc:title xml:lang="sl">Pomen serumskega cistatina C za ugotavljanje okvare ledvic med kemoterapijo|</dc:title><dc:description xml:lang="sl">Many cytotoxic agents used in antitumor therapies can cause a kidney damage. Therefore there is a necessity for regular kidney function monitoring before and during chemotherapy. Clearance tests have been proven to be the most accurate indicators for clinical assessment of glomerular filtration (CFR). Because of inconvenience of exogene markers (inulin, 51Cr-EDTA), endogenous creatinine clearance (ECC) is used in everyday routine work. Results obtained from ECC analysis can often be misleading due to inaccurate urine collectin. In order to avoid the inconvenient urine collecting, we are trying to find an easier and faster way of kidney function assessment. Cystatin C is a serum protein, which is a member of the cysteine proteinase inhibitors. It is produced by all nucleal cells and its production rate is independent of sex, nutrition status, acute and chronic diseases and cancer. Because it is freely filtered at the glomerulus, its serum concentration correlates with glomerularfiltration rate. The purpose of this research was to find out if theserum cystatine C concentration correlates with GFR and ECC respectively. We analysed 117 serum samples taken from 56 patients. Serum and urine creatinine concentrations were determined by method based on Jaffe reaction, ECC: was calculated from urine flow, surface area and the ratio between serum and urine creatinine concentrations. We used particle enhanced turbidimetric immunoassay (PET) for cystatin C determination. Data were statistically analysed with SimStat computer program. We used Pearson correlation method with 95% confidence interval. A good correlation coefficient (r =0.736) between the values of serum creatinine and cystatine C was established within the whole concentration interval. (Abstract truncated at 2000 characters.)</dc:description><dc:description xml:lang="sl">Mnoge citotoksične učinkovine, ki jih uporabljamo pri zdravljenju raka, lahko okvarijo delovanje ledvic, zato moramo pred in med kemoterapijo redno spremljati delovanje ledvic. Za oceno njihovega delovanja in zgodnjih okvar sonajpomembnejši testi očistkov. V vsakodnevni klinični praksi delovanje ledvic vrednotimo z očistkom kreatinina (endogenous creatinine clearance - ECC), saj so preiskave s pomočjo eksogenih označevalcev (npr. inulin, 51Cr-EDTA) nepraktične in obremenjujoče za bolnika. Pri določanju ECC lahko pride do zavajajočih rezultatov zaradi nedoslednosti bolnika pri zbiranju celodnevnega seča. Da bolnikom ne bi bilo treba zbirati seča, poskušamo odkriti enostavnejši in hitrejši način ugotavljanja ledvične funkcije. Cistatin C je serumska beljakovina, ki jo uvrščamo med inhibitorje cisteinskihproteaz. Nastaja v vseh jedrnih celicah. Njegova serumska koncentracija je neodvisna od spola, stanja prehranjenosti, akutnih in kroničnih bolezni ter raka. Ker se v večini izloča skozi glomerule, njegova serumska koncentracija korelira z glomerulno filtracijo (GFR). Namen naloge jebil ugotoviti, ali koncentracija serumskega cistatina C korelira z GFR oziroma z ECC. V raziskavi smo analizirali 117 vzorcev pri 56 bolnikih. Kreatinin v serumu in seču smo določali z metodo, ki temelji na Jaffejevi reakciji, ECC smo izračunali iz volumskega pretoka seča, telesne površine in razmerja med koncentracijo kreatinina v serumu in seču, cistatin C smo določili s turbidimetrično analizno tehniko PET. Podatke smo statistično obdelali s programom SimStat. Korelacijske koeficiente smo računali po Pearsonu v 95 % intervalu zaupanja. Pri primerjavi vrednosti serumskega kreatinina in cistatina C smo ugotovili visoko povezanost (r = 0,736) za celotno koncentracijsko območje. Odnos med vrednostmi cistatina C in ECC je določen s korelacijskim koeficientom r = 0,792. Pri 117 vzorcih se je cistatinC razlikoval od ECC v 8 primerih (6,8 %). (Izvleček prekinjen pri 2000znakih)</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-BX3V6XLQ"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-BX3V6XLQ" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-BX3V6XLQ/d3885879-bc0e-4ecd-92ab-3a0f11000bbc/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo Medicinski razgledi</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-BX3V6XLQ/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-BX3V6XLQ" /></ore:Aggregation></rdf:RDF>